Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Terminated · Phase 2 · NCT05023655
Conditions: Solid Tumor, ARID1A Gene Mutation
At a glance
- Research payments reported, 2025
- $13,055
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- Prisma Health-Upstate (with Ipsen)
- Tested
- Tazemetostat (drug)
- Dates
- Started 2022-01-06; completion 2026-03-06
- Results posted
- Not yet
The FDA approved targeted agent tazemetostat inhibits EZH2 and induces durable tumor responses in patients with B-cell non-Hodgkin's lymphoma and epithelioid sarcomas. Responses have also been demonstrated in INI1 and SMARCA4 negative solid tumors patients. Since EZH2 plays a critical role in driving the biology of ARID1A mutated malignancies, we hypothesize that inhibition of EZH2 with tazemetostat will lead to significant clinical benefit in ARID1A mutated malignancies.
From ClinicalTrials.gov, last updated 2026-03-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $13,055 in research payments for this study in 2025 (2 payments).
Products named: Tazverik
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.